PM 226
Modify Date: 2025-08-25 18:35:24
PM 226 structure
|
Common Name | PM 226 | ||
|---|---|---|---|---|
| CAS Number | 1949726-13-9 | Molecular Weight | 357.49 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H31NO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PM 226PM226 is a selective cannabinoid CB2R agonist (Ki (CB2)=13 nM; EC50 (CB2)=39 nM; Ki (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo[1]. |
| Name | PM226 |
|---|
| Description | PM226 is a selective cannabinoid CB2R agonist (Ki (CB2)=13 nM; EC50 (CB2)=39 nM; Ki (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo[1]. |
|---|---|
| Related Catalog | |
| Target |
CB2:13 nM (Ki) CB2:39 nM (EC50) |
| In Vitro | PM226 binds selectively to CB2 receptor with an affinity in the nanomolar range (Ki=12.8±2.4 nM). PM226 has negligible affinity for the CB1 receptor (Ki >40000 nM) and no activity at the GPR55. PM226 was also evaluated in GTPγS binding assays specific to the CB2 receptor showing agonist activity (EC50=38.67±6.70 nM)[2]. |
| In Vivo | PM226 (0.1, 1 and 10 mg/kg; administered i.p.) administration decreases the volume of the striatal lesion caused by Malonate[2]. Animal Model: Malonate-lesioned adult (12 week old; 350-400 g) male Wistar rats[2] Dosage: 0.1, 1 and 10 mg/kg Administration: Administered i.p. Result: Reduced the volume of edema observed in Malonate-lesioned rats at the dose of 1 mg/kg. |
| References |
| Molecular Formula | C22H31NO3 |
|---|---|
| Molecular Weight | 357.49 |